Having trouble accessing articles? Reset your cache.

Cymbalta duloxetine regulatory update

FDA's Anesthetic and Life Support Drugs Advisory Committee voted 8-6 in favor of approving an sNDA to expand the pain indications for Eli Lilly's Cymbalta duloxetine. The panel

Read the full 280 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE